Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1) | BioLegend 329735 product information

product summary

company name :

BioLegend

other brands :

Babco, Signet, Sternberger Monoclonals, Senetek, Covance

product type :

antibody

product name :

Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1)

catalog :

329735

quantity :

25 tests

price :

215 USD

clonality :

monoclonal

host :

mouse

conjugate :

Brilliant Violet 785

clone name :

29E.2A3

reactivity :

human

application :

flow cytometry, blocking or activating experiments

more info or order :

BioLegend product webpage

citations: 15

Published Application/Species/Sample/Dilution	Reference
blocking or activating experiments; human; loading ...; fig 6c	Lin A, Twitty C, Burnett R, Hofacre A, Mitchell L, Espinoza F, et al. Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. Mol Ther Nucleic Acids. 2017;6:221-232 pubmed publisher
flow cytometry; human; loading ...; fig 1d	Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, et al. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Sci Rep. 2017;7:42687 pubmed publisher
flow cytometry; human; 1:100; fig 5a	Beatson R, Tajadura Ortega V, Achkova D, Picco G, Tsourouktsoglou T, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17:1273-1281 pubmed publisher
flow cytometry; human; fig 4	Seifert A, Zeng S, Zhang J, Kim T, Cohen N, Beckman M, et al. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454-465 pubmed publisher
flow cytometry; human; loading ...; fig s1	Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, et al. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clin Cancer Res. 2017;23:149-158 pubmed publisher
flow cytometry; human; fig s6b	Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
blocking or activating experiments; human flow cytometry; human; fig 7	Jutz S, Leitner J, Schmetterer K, Doel Perez I, Majdic O, Grabmeier Pfistershammer K, et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-ÎºB, NFAT and AP-1. J Immunol Methods. 2016;430:10-20 pubmed publisher
flow cytometry; human; loading ...; fig 1	Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
flow cytometry; human; fig 2	Du Z, Abedalthagafi M, Aizer A, McHenry A, Sun H, Bray M, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6:4704-16 pubmed
flow cytometry; human; fig 4	Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51 pubmed publisher
	Arenas E, Martínez Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Nat Commun. 2021;12:1237 pubmed publisher
	Goodwin M, Lee E, Lakshmanan U, Shipp S, Froessl L, Barzaghi F, et al. CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells. Sci Adv. 2020;6:eaaz0571 pubmed publisher
	Rosenbaum S, Knecht M, Mollaee M, Zhong Z, Erkes D, McCue P, et al. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020;30:510-524.e6 pubmed publisher
	Hunegnaw R, Mushtaq Z, Enyindah Asonye G, Hoang T, Robert Guroff M. Alveolar Macrophage Dysfunction and Increased PD-1 Expression During Chronic SIV Infection of Rhesus Macaques. Front Immunol. 2019;10:1537 pubmed publisher
	Maute R, Gordon S, Mayer A, McCracken M, Natarajan A, Ring N, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015;112:E6506-14 pubmed publisher

product information

Antigen :

CD274

Apps. Abbrev. :

Flow Cytometry

Cat # :

329735

Clone :

29E.2A3

Item :

Brilliant Violet 785™ anti-human CD274 (B7-H1, PD-L1)

Isotype :

Mouse IgG2b, κ

Other Names :

Programmed cell death ligand 1 (PD-L1), B7 homolog 1 (B7-H1)

Size :

25 tests

Price (USD) :

215 USD

Reactivity :

Human

Clonality :

Monoclonal

Host :

Mouse

Conjugate/Tag/Label :

BV785

Immunogen :

Full length human PD-L1

Application Notes :

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region 5 . Additional reported applications (for the relevant formats) include: blocking 1-3 and immunohistochemical staining of acetone-fixed frozen sections 1 . The Ultra-LEAF purified antibody (Endotoxin 0.01 EU/ug, Azide-Free, 0.2 um filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748). It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the Alexa Fluor 700 conjugate of interest. . Clone 29E.2A3 does not work in Western blot applications 7 .

more info or order :

BioLegend product webpage